• 主页
  • 查找结果
  • Distinct phenotype of a Wilson disease mutation reveals a novel trafficking determinant in the copper transporter ATP7B.

Distinct phenotype of a Wilson disease mutation reveals a novel trafficking determinant in the copper transporter ATP7B.

Proceedings of the National Academy of Sciences of the United States of America (2014-04-08)
Lelita T Braiterman, Amrutha Murthy, Samuel Jayakanthan, Lydia Nyasae, Eric Tzeng, Grazyna Gromadzka, Thomas B Woolf, Svetlana Lutsenko, Ann L Hubbard
摘要

Wilson disease (WD) is a monogenic autosomal-recessive disorder of copper accumulation that leads to liver failure and/or neurological deficits. WD is caused by mutations in ATP7B, a transporter that loads Cu(I) onto newly synthesized cupro-enzymes in the trans-Golgi network (TGN) and exports excess copper out of cells by trafficking from the TGN to the plasma membrane. To date, most WD mutations have been shown to disrupt ATP7B activity and/or stability. Using a multidisciplinary approach, including clinical analysis of patients, cell-based assays, and computational studies, we characterized a patient mutation, ATP7B(S653Y), which is stable, does not disrupt Cu(I) transport, yet renders the protein unable to exit the TGN. Bulky or charged substitutions at position 653 mimic the phenotype of the patient mutation. Molecular modeling and dynamic simulation suggest that the S653Y mutation induces local distortions within the transmembrane (TM) domain 1 and alter TM1 interaction with TM2. S653Y abolishes the trafficking-stimulating effects of a secondary mutation in the N-terminal apical targeting domain. This result indicates a role for TM1/TM2 in regulating conformations of cytosolic domains involved in ATP7B trafficking. Taken together, our experiments revealed an unexpected role for TM1/TM2 in copper-regulated trafficking of ATP7B and defined a unique class of WD mutants that are transport-competent but trafficking-defective. Understanding the precise consequences of WD-causing mutations will facilitate the development of advanced mutation-specific therapies.

材料
货号
品牌
产品描述

Sigma-Aldrich
铜, powder, <425 μm, 99.5% trace metals basis
Sigma-Aldrich
铜, powder, 99.999% trace metals basis
Sigma-Aldrich
铜, foil, thickness 0.25 mm, 99.98% trace metals basis
Sigma-Aldrich
铜, wire, diam. 1.0 mm, ≥99.9%
Sigma-Aldrich
铜, powder, <75 μm, 99%
Sigma-Aldrich
铜, powder (spheroidal), 10-25 μm, 98%
Sigma-Aldrich
铜, ACS reagent, granular, 10-40 mesh, ≥99.90%
Sigma-Aldrich
铜, nanopowder, 60-80 nm particle size (SAXS), ≥99.5% trace metals basis
Sigma-Aldrich
铜, nanopowder, 40-60 nm particle size (SAXS), ≥99.5% trace metals basis
Sigma-Aldrich
铜, electrolytic, Analytical Reagent, reag. Ph. Eur., ≥99.9% (complexometric), wire
Sigma-Aldrich
铜, foil, thickness 0.025 mm, 99.98% trace metals basis
Sigma-Aldrich
铜, foil, thickness 1.0 mm, 99.999% trace metals basis
Sigma-Aldrich
铜, powder (dendritic), <45 μm, 99.7% trace metals basis
Sigma-Aldrich
铜, foil, thickness 0.5 mm, 99.98% trace metals basis
Sigma-Aldrich
铜, turnings, purum p.a., ≥99.0%
Sigma-Aldrich
铜, foil, ≥99.8% (complexometric)
Sigma-Aldrich
铜, wire, diam. 0.25 mm, 99.999% trace metals basis
Sigma-Aldrich
铜, beads, 2-8 mm, ≥99.99% trace metals basis
Sigma-Aldrich
铜, beads, 2-8 mm, 99.9995% trace metals basis
Sigma-Aldrich
铜, wire, diam. 2.0 mm, 99.999% trace metals basis
Sigma-Aldrich
铜, wire, diam. 0.64 mm, 99.995% trace metals basis
铜, foil, 150x150mm, thickness 0.20mm, hard, 99.95+%
铜, wire reel, 100m, diameter 0.05mm, annealed, 99.9%
铜, wire reel, 1000m, diameter 0.1mm, annealed, 99.9%
铜, wire reel, 5m, diameter 0.025mm, as drawn, 99.99+%
铜, wire reel, 1000m, diameter 0.125mm, annealed, 99.9%
铜, foil, 150x150mm, thickness 0.125mm, hard, 99.95+%
铜, rod, 100mm, diameter 4.8mm, hard, 99.9%
铜, tube, 100mm, outside diameter 2.0mm, inside diameter 1.6mm, wall thickness 0.2mm, as drawn, 99.9%
铜, tube, 100mm, outside diameter 2.5mm, inside diameter 1.9mm, wall thickness 0.3mm, as drawn, 99.9%

社交媒体

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

科研、开发、生产。

作为生命科学行业的全球领先供应商,我们致力于为科研、生物技术开发和生产,以及制药药物疗法开发和生产提供各类解决方案和服务。

© 2021年版权归德国达姆施塔特默克集团(Merck KGaA)及/或其附属公司所有。版权所有。

未经许可,严禁复制本网站上的任何资料。